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Coronavirus disease 2019 (COVID‐19) is caused by a contagious virus that has
spread to more than 200 countries, territories, and regions. Thousands of studies to
date have examined all aspects of this disease, yet little is known about the post-
recovery status of patients, especially in the long term. Here, we examined ery-
throcyte sedimentation rate (ESR), C‐reactive protein (CRP), and serum albumin
biomarkers in patients with a history of severe and mild‐to‐moderate COVID‐19
following their recovery. In patients with severe COVID‐19 serum albumin had a
strong negative correlation with both ESR and CRP levels (R2 = − 0.861 and
R2 = − 0.711), respectively. Also, there was a positive correlation between ESR and
CRP level (R2 = 0.85) in the same group. However, there was no correlation between
these biomarkers among mild‐to‐moderate COVID‐19 patients. In addition, no
correlation was recorded between the severe and mild‐to‐moderate COVID‐19
groups. This finding highlights the sustained elevation of ESR and CRP level and
reduced serum albumin level that may persist postrecovery in patients with a his-
tory of severe COVID‐19.
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1 | INTRODUCTION
Beginning in late December 2019 in Wuhan, China,1 the ongoing cor-
onavirus disease 2019 (COVID‐19) pandemic, which was caused by the
spread of a novel coronavirus, severe acute respiratory syndrome cor-
onavirus 2 (SARS‐CoV‐2)—named for the similarity of its symptoms to
those induced by the SARS‐CoV‐22—achieved worldwide reach within
3 months of its discovery.3,4 Accordingly, on 11 March 2020, the World
Health Organization labeled COVID‐19 as pandemic disease.5
Patients with COVID‐19 may show flu‐like symptoms such as
fever, cough, dyspnea, myalgia, and fatigue. Those with serious forms
of the disease can experience severe pneumonia, respiratory failure,
multiorgan dysfunction, and death.6,7 Gastrointestinal symptoms
such as diarrhea, nausea, and vomiting have also been reported,
along with a loss of the senses of taste and smell.8,9 Since the start of
the initial outbreak, scientists have made grade strides in under-
standing the pathophysiology and progression of this disease.10–12
The clinical manifestations of patients infected with SARS‐CoV‐2
can be stratified as mild, moderate, severe, and critical.13 The ma-
jority of affected patients (81%) suffer mild/moderate symptoms,
whereas severe and critical cases total 14% and 5% of infected cases,
respectively.14
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Several biological markers have been found to correlate with the
severity of COVID‐19, including high C‐reactive protein (CRP) level,
high erythrocyte sedimentation rate (ESR), and low serum albumin
level (hypoalbuminemia).11,15–17 These biomarkers in parallel with
clinical symptoms can be used to determine with greater confidence
the likely progression and severity of the disease in a certain case.18
CRP is an exquisitely sensitive systemic marker for the acute phase
response to inflammation, infection, and tissue damage19 and it has
been reported that CRP levels are positively correlated with the
severity of COVID‐19.20 Another study reported the observation of
high ESR levels in patients suffering severe COVID‐19 symptoms
relative to those with less severe disease due to an increase in the
inflammation inherent in the former group.15 In addition, other stu-
dies have suggested the serum albumin level to be a vital indicator of
status in patients with severe COVID‐19.17,21
Since the appearance of COVID‐19 on the global stage, much
research has been conducted regarding this disease.10–12,18 To date,
however, even though millions of people have recovered from this
condition, limited follow‐up studies exist that have focused on the
postrecovery health status of these individuals.22 Here, we examined
the ESR, CRP levels, and serum albumin levels postrecovery in pa-
tients with a history of severe COVID‐19 and compared the col-
lected values with the same parameters in a population with a
history of mild‐to‐moderate COVID‐19.
2 | MATERIALS AND METHODS
2.1 | Real‐time reverse transcription polymerase
chain reaction assay for SARS‐CoV‐2
A total of 46 hospitalized patients were included in this study. The
diagnostic tests were performed for each patient, and pharyngeal
swab samples collected for extracting 2019‐nCoV RNA. After col-
lection, the total RNA was automatically extracted within 45min
using the Qiagen EZ1 Advanced XL system (Qiagen). Then, the pre-
sence of SARS‐CoV‐2 was detected by real‐time reverse
transcription‐polymerase chain reaction (RT‐PCR) amplification of
SARS‐CoV‐2 open reading frame 1ab (ORF1ab) and envelope (E)
genes fragments using PowerChek SARS‐CoV‐2 Real‐Time PCR Kit
(KogeneBiotech). Conditions for amplification were 50°C for 30min,
95°C for 10min, followed by 40 cycles of 95°C for 15 s and 60°C for
1min. When two target genes (ORF1ab, E) tested positive by
specific real‐time RT‐PCR, the case would be transferred to the la-
boratory for confirmation. A cycle threshold value (Ct‐value) ≤ 36.7
was defined as a positive test, and the Ct‐value of greater than 36.7
was defined as a negative test or recovered.
2.2 | COVID‐19 severity category
The criteria for severity of COVID‐19 were defined according to the
diagnosis and treatment protocol for novel coronavirus pneumonia
(Version 7) as mild, moderate, and severe.23 Mild cases the patient
shows mild clinical symptoms with no sign of pneumonia on imaging;
moderate cases the patient shows fever and respiratory symptoms with
radiological findings of pneumonia; severe cases have any of the fol-
lowing criteria, respiratory distress (≧30 breaths/min), oxygen satura-
tion ≤93% at rest, arterial partial pressure of oxygen (PaO2)/fraction of
inspired oxygen (FiO2)≦300mmHg (1mmHg= 0.133 kPa).
Postrecovery, means the time period after recovery when the
COVID‐19 patients discharged from the hospital and COVID‐19
signs and symptoms disappeared after the negative RT‐PCR24 that
is, returning to a normal or healthy state after a period of COVID‐19
disease. Based on, blood samples were collected from recovered
COVID‐19 patients within 2–4 weeks (with a mean of 20.6 ± 3.3
days) after their negative RT‐PCR.
Considering the above criteria, recovered patients were divided
into two groups; 23 mild–moderate cases and 23 severe post-
recovered COVID‐19 cases.
2.3 | Biological marker test
Biological marker tests including CRP and serum albumin were as-
sessed for mild, moderate, and severe groups using an automated
multiparametric analyzer (Cobas c111; Roche Diagnostics) and ESR
were tested by the Westergren method.25
2.4 | Ethics declarations
All methods were carried out in accordance with the relevant
guidelines and regulations. Also, we confirm that all experimental
protocols were approved by the Ethics Licensing Committee of the
Kalar Technical Institute at the Sulaimani Polytechnic University
Committee (No. 01 on August 1, 2020). In addition, informed consent
was obtained from all subjects or if subjects are under 18, from a
parent and/or legal guardian.
2.5 | Statistical analysis
Pearson correlation and polynomial regressions were employed to
understand the relationship between ESR, CRP, and serum albumin
biomarkers between mild, moderate, and severe postrecovery
COVID‐19 patients. Also, an unpaired T‐test has been used to study
differences of body weight loss between both groups.
3 | RESULTS AND DISCUSSION
Patients infected with SARS‐CoV‐2 can be assessed clinically by
using quantitative measurements of numerous biomarkers such
as ESR, CRP level, and serum albumin level. Monitoring of those
biomarkers could play a key role in reviewing the pathological
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development and suggesting the prognosis and outcomes of the
disease.26
In this study, all cases were identified by RT‐PCR and categorized
into two groups (mild‐to‐moderate and severe) according to the status of
their disease. ESR, CRP levels, and serum albumin levels were measured
in both groups and we found that albumin had a strong negative cor-
relation with ESR (R2 =−0.861) and CRP level (R2 =−0.711) post-
recovery in patients with a history of severe COVID‐19 (Table 1).
Hypoalbuminemia is seen more predominantly in severe
COVID‐19 cases than mild cases.27 However, no study has yet
evaluated the levels of albumin nor the effect of such on the
health of patients with a history of COVID‐19 after their re-
covery. In our study, we observed persistent hypoalbuminemia
postrecovery in patients with a history of severe COVID‐19.
Although the mechanisms for hypoalbuminemia in COVID‐19
have not been studied thoroughly,28 albumin is considered a
major serum protein produced by hepatic cells,28,29 and has a
critical role in human health. As such, hypoalbuminemia is con-
sidered a sinister clinical sign in COVID‐19 viral infection that
may be attributed to the release of major acute phase cytokines
into the blood vessels during cytokine storm17 or due to an in-
crease in vascular permeability, which allows the albumin to
diffuse into the extravascular space.30 A reduction in albumin
synthesis may also be the result of anorexia caused by SARS‐
CoV‐2 viral infection.17 Thus, a high protein nutrition and even-
tual albumin administration to the COVID‐19 patients should be
considered.
In the present study, we found that ESR increased in all severe
COVID‐19 postrecovery patients. Similar results were found by
Pu et al.31 who observed an elevated level of ESR in a case study of a
patient recovered from severe COVID‐19 infection. This finding may
justify the strong negative correlation between ESR and albumin because
albumin retards the sedimentation of erythrocytes and decreases the
rouleaux formation while hypoalbuminemia accelerates it,32 in contrary
to other plasma proteins in which high level of them speed it up.33
Our study revealed a high concentration of CRP in severe
COVID‐19 postrecovery patients. A significant negative correlation
was also found between albumin level and the inflammatory indicator,
CRP (R2 = − 711) (Table 1). Studies have determined a significant in-
crease of CRP concentration in severe COVID‐19 patients.34–36
However, our data are the first study related to the COVID‐19
postrecovery patients. CRP is produced by the liver as a nonspecific
immune protein and it is considered as a signal of systemic in-
flammation37 CRP level in serum also can be affected with the level of
other serum proteins which are produced by liver cells.38,39
Ponti et al.40 found the severity of COVID‐19 is positively cor-
related with ESR and CRP, while no study on both biomarkers after
the recovery of COVID‐19 patients has been recorded yet. Our data
has revealed a positive correlation between ESR and CRP (R2 = 0.85)
in severe COVID‐19 postrecovery patients. Elevation of in-
flammatory biomarkers can be considered as a parameter for
COVID‐19 infection and its severity.26
In the mild–moderate COVID‐19 postrecovery group, our data
showed nonsignificant positive correlation between ESR and CRP
(0.6149). In addition, in the same group there was neither correlation
between CRP and albumin (–0.3277) nor between ESR and albumin
(−0.0504; Table 1). Several studies have revealed low ESR and CRP in
mild–moderate COVID‐19 patients,40‐42 while other studies showed
a slight decrease of serum albumin in the same group when com-
pared with severe cases.41,43 Most importantly no studies conducted
on postrecovery patients addressing changes in those markers yet. In
mild–moderate COVID‐19 patients the inflammatory proteins that
have an effect on ESR boosting maintain in their minimum level,
subsequently ESR stays in their normal range.44 Our study seems to
be one of the first attempts to observe those biological markers in
COVID‐19 postrecovery patients.
In Table 1, data analyses showed no correlation between mild,
moderate, and severe groups in COVID‐19 postrecovery patients
when both groups compared each other in terms of ESR, CRP, and
serum albumin markers.
A study by Kermali et al.26 showed a significant difference in
ESR, CRP, and serum albumin between mild and severe COVID‐19
patients. However, the difference between moderate and severe
groups was observed only in ESR.
TABLE 1 Correlation analysis between ESR, CRP, and albumin









ESR severe 1.0000 0.8534 −0.8610 0.1206 0.0868 −0.3505
CRP severe 0.8534 1.0000 −0.7114 −0.0487 −0.0457 −0.3242
Serum albumin severe −0.8610 −0.7114 1.0000 0.0784 0.1265 0.2419
ESR mild–moderate 0.1206 −0.0487 0.0784 1.0000 0.6149 −0.0504
CRP mild–moderate 0.0868 −0.0457 0.1265 0.6149 1.0000 −0.3277
Serum albumin
mild–moderate
−0.3505 −0.3242 0.2419 −0.0504 −0.3277 1.0000
Note: In severe COVID‐19 postrecovery group and mild/moderate COVID‐19 postrecovery group. Also, correlation analysis between severe and mild/
moderate COVID‐19 postrecovery groups, n = 46 patients.
Abbreviations: COVID‐19, coronavirus disease 2019; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate.
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The present study showed a significant difference in the body weight
loss between mild, moderate, and severe postrecovery COVID‐19 pa-
tient groups (p<0.0005), body weight loss average for mild–moderate
group was 1.43 ±1.38, while for the severe group was 4.17± 1.95
(Figure 1). Several factors may contribute to body weight loss and mal-
nutrition in COVID‐19 patients,45,46 such as; systemic inflammation, high
CRP level,46 hypoalbuminemia, inadequate protein, and caloric intake.
Also, inflammation induces anorexia, reduces the effective use of dietary
protein and energy intake, and augments catabolism of the key somatic
protein, albumin which has consequences on body weight loss.47
In conclusion, we found a prolonged increase of ESR, CRP, and de-
crease of serum albumin in severe COVID‐19 postrecovery patients. We
also discovered a strong negative correlation of albumin with both ESR
and CRP in the group. Therefore, further study on albumin administra-
tion and ESR/CRP de‐escalation is recommended which helps COVID‐19
postrecovery patients to avoid further consequences of the disease.
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